Blog

Learn how to choose the right DNA sequencing service based on your research goals, read length, accuracy, turnaround time, cost, and data requirements. Compare Sanger, NGS, and Nanopore sequencing.

Whole plasmid sequencing, powered by Nanopore Technology. Complete end-to-end plasmid validation, beyond sanger & short-read NGS

From intelligent molecular design to experimental validation, AI is reshaping how the next generation of antibody therapeutics is discovered, optimized, and developed.

Golden Gate Cloning has become one of the most powerful molecular biology techniques for synthetic biology, plasmid construction, metabolic engineering, and CRISPR applications. By leveraging the unique properties of Type IIS restriction enzymes, researchers can assemble multiple DNA fragments in a single reaction with remarkable efficiency and accuracy.

CRISPR gene editing has become a cornerstone technology in modern life science research, enabling precise modifications in genomes across a wide range of organisms. However, successful gene editing does not end with the editing step itself. Researchers must verify whether the intended edit has occurred accurately and efficiently. This makes CRISPR validation a critical component of every genome editing workflow.

Long gene synthesis has become a foundational technology in synthetic biology, protein engineering, gene therapy, vaccine development, and industrial biotechnology. While synthesizing short DNA fragments is now routine, constructing genes longer than 3 kb—and especially those exceeding 10 kb—still presents significant technical challenges. Successful long gene synthesis requires more than simply ordering DNA. Researchers must carefully consider sequence design, assembly strategy, error management, and downstream validation to ensure project success.

Sanger sequencing, often referred to as the chain-termination method, remains one of the most trusted and widely used DNA sequencing technologies in modern molecular biology. Developed by Frederick Sanger in 1977, it delivers exceptional accuracy and clear,

Messenger RNA (mRNA) holds great potential for vaccines, protein replacement therapy, cancer immunotherapy, in vivo cell therapy and gene editing. However, naked mRNA faces critical barriers for in vivo administration: it is rapidly degraded by ubiquitous ribonucleases in bodily fluids, triggers strong innate immune responses, and cannot spontaneously cross negatively charged cell membranes.

​In vitro transcription (IVT) has become the foundational manufacturing technology for modern mRNA-based modalities, including prophylactic vaccines, cancer immunotherapies, protein replacement agents, in vivo cell therapies and gene editing systems. Despite widespread adoption, lab-scale mRNA synthesis continues to face persistent technical challenges: